This site uses cookies to ensure the best viewing experience for our readers.
Gastro Treatment Company RedHill Announces Successful Clinical Trial in Treatment of H. Pylori Infection

Brief

Gastro Treatment Company RedHill Announces Successful Clinical Trial in Treatment of H. Pylori Infection

RedHill’s new pill managed to eradicate 84% of H. pylori bacteria, as opposed to 58% in patients receiving the standard of care

CTech | 16:10  04.12.2018
Nasdaq and Tel Aviv-listed pharmaceutical company RedHill Biopharma Ltd. announced Monday it has received positive results for its antibiotic treatment of Helicobacter pylori gastric infections, the company announced Monday. In a stage 3 study conducted by the company, RedHill’s new pill TALICIA, which combines the antibiotics rifabutin and amoxicillin, managed to eradicate 84% of H. pylori bacteria, as opposed to 58% in patients receiving the standard of care. H. pylori is a type of gastric bacteria, linked with increased risks of developing ulcers and cancer.

Founded in 2009, Tel Aviv-headquartered RedHill develops orally-administered medicine for gastrointestinal and inflammatory diseases. RedHill is traded at a market capitalization of $207 million, as of market close Monday.

Redhill pills. Photo: PR Redhill pills. Photo: PR Redhill pills. Photo: PR

share on facebook share on twitter share on linkedin share on whatsapp share on mail

TAGS